Inside the magazine
WAITING FOR THE OUTBREATH – WHAT CAN COVID-19 BIOAEROSOL RESEARCH TELL US ABOUT INHALABLE DRUG DELIVERY?
Deborah Norris, Mark Allen, Karl Hewson and Karla Sanchez, discuss how the covid-19 pandemic has spurred research in the pulmonary space, which suggests that a patient-tailored approach based on their individual lung characteristics, facilitated by advanced technology, could improve patient health outcomes and quality of life.
Siamac Parker, Sion Coulman, Prof James Birchall alongside Susana Ecenarro and Mahmoud Farag, present a study that uses optical coherence tomography to characterise the wall thickness of capsules at the dome position and investigates the importance of controlling the dome thickness of hard-shell capsules to be used in a dry powder inhaler.
Frédérique Bordes-Picard of Lonza, Marco Franza of Berry, Mirjam Kobler of Meggle, and Marco Laackmann of Harro Höfliger, discuss the accelerating development potential of capsule-based dry powder inhalers (DPIs) and the potential of these effective and efficient drug delivery devices in the modern drug delivery market.
Bas van Driel discusses how expert collaborations can help develop a knowledge base to transform drug delivery and manufacturing. He shares how recent collaborative research projects involving lactose-based dry powder inhalation formulations, with and without magnesium stearate and lactose as an excipient in 3D tablet printing, have done just that.